NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $360,010 | -88.0% | 18,731 | -84.1% | 0.00% | -100.0% |
| Q2 2023 | $2,988,197 | -35.5% | 117,553 | -8.2% | 0.00% | -33.3% |
| Q1 2023 | $4,629,911 | -43.3% | 128,075 | -37.9% | 0.00% | -40.0% |
| Q4 2022 | $8,162,748 | +7.1% | 206,130 | +26.0% | 0.01% | 0.0% |
| Q3 2022 | $7,622,000 | +41.8% | 163,547 | +33.3% | 0.01% | +66.7% |
| Q2 2022 | $5,375,000 | -79.9% | 122,645 | -66.8% | 0.00% | -75.0% |
| Q1 2022 | $26,693,000 | +606.7% | 369,028 | +692.0% | 0.01% | +500.0% |
| Q4 2021 | $3,777,000 | -30.9% | 46,593 | -0.8% | 0.00% | -33.3% |
| Q3 2021 | $5,467,000 | -60.1% | 46,980 | -43.2% | 0.00% | -57.1% |
| Q2 2021 | $13,709,000 | +47.3% | 82,688 | +24.0% | 0.01% | +40.0% |
| Q1 2021 | $9,305,000 | -11.4% | 66,700 | +9.9% | 0.01% | -16.7% |
| Q4 2020 | $10,502,000 | +40.7% | 60,678 | +13.2% | 0.01% | +20.0% |
| Q3 2020 | $7,466,000 | +27.0% | 53,596 | +9.0% | 0.01% | +25.0% |
| Q2 2020 | $5,877,000 | -19.7% | 49,187 | -32.8% | 0.00% | -42.9% |
| Q1 2020 | $7,318,000 | +71.0% | 73,195 | +100.9% | 0.01% | +133.3% |
| Q4 2019 | $4,280,000 | +295.6% | 36,429 | +189.0% | 0.00% | +200.0% |
| Q3 2019 | $1,082,000 | -88.9% | 12,606 | -91.6% | 0.00% | -83.3% |
| Q2 2019 | $9,772,000 | -64.2% | 150,759 | -65.5% | 0.01% | -62.5% |
| Q1 2019 | $27,325,000 | +128.5% | 437,162 | +42.1% | 0.02% | +100.0% |
| Q4 2018 | $11,961,000 | -58.4% | 307,606 | -39.1% | 0.01% | 0.0% |
| Q3 2018 | $28,764,000 | -30.0% | 504,686 | -1.9% | 0.01% | -33.3% |
| Q2 2018 | $41,070,000 | +137.1% | 514,365 | +157.3% | 0.01% | +50.0% |
| Q1 2018 | $17,321,000 | -67.1% | 199,887 | -73.8% | 0.01% | -76.5% |
| Q4 2017 | $52,681,000 | -48.5% | 763,082 | -32.2% | 0.03% | -51.4% |
| Q3 2017 | $102,336,000 | +156.8% | 1,126,088 | +110.3% | 0.07% | +150.0% |
| Q2 2017 | $39,852,000 | +2135.1% | 535,449 | +2711.1% | 0.03% | +2700.0% |
| Q1 2017 | $1,783,000 | -83.2% | 19,048 | -87.0% | 0.00% | -88.9% |
| Q4 2016 | $10,604,000 | -38.0% | 145,969 | -10.9% | 0.01% | -25.0% |
| Q3 2016 | $17,105,000 | +26.8% | 163,871 | -10.4% | 0.01% | +20.0% |
| Q2 2016 | $13,485,000 | +110.9% | 182,845 | +60.9% | 0.01% | +100.0% |
| Q1 2016 | $6,393,000 | -54.5% | 113,669 | -45.4% | 0.01% | -50.0% |
| Q4 2015 | $14,057,000 | +6468.7% | 208,242 | +4406.4% | 0.01% | – |
| Q3 2015 | $214,000 | -93.0% | 4,621 | -91.9% | 0.00% | -100.0% |
| Q2 2015 | $3,071,000 | – | 57,158 | +476216.7% | 0.00% | – |
| Q1 2015 | $0 | – | 12 | +200.0% | 0.00% | – |
| Q4 2014 | $0 | – | 4 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |